Aclarion Inc. (NASDAQ: ACON, ACONW) published a shareholder letter from CEO Brent Ness outlining the company's strategic priorities for 2026, according to a press release statement.

The healthcare technology company is pursuing reimbursement coverage from regional insurance providers in the United States for its Nociscan platform, which uses biomarkers and algorithms to help physicians identify chronic low back pain sources. The company expects an initial readout from its CLARITY clinical trial in the fourth quarter of 2026.

Aclarion reported having cash runway extending into 2028. The company stated it is expanding adoption of its Nociscan platform and advancing reimbursement initiatives in both the United Kingdom and United States.

"Our focus in 2026 remains disciplined execution against the key catalysts that we believe can expand adoption of Nociscan and strengthen the clinical and reimbursement foundation of our business," Ness said in the letter.

The Nociscan platform receives magnetic resonance spectroscopy data from MRI machines through a cloud connection to analyze lumbar discs. The system processes chemical biomarkers associated with disc pain and uses algorithms to indicate potential pain sources.

The company is continuing commercial engagement with physicians and imaging centers while building clinical evidence for its platform. The full CEO letter is available on the company's website.